• Ranjana Advani
  radvani@stanford.edu

  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Speaker)
  • 28.10., 10:30–12:00, Biology & Microenvironment (Abstract talk)
• Pamela Allen
  pallen@emory.edu

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Poster pitch)
• Marc André
  marc.andre@uclouvain.be

  • 28.10., 14:00–15:30, Early Stages (Speaker)
• Stephen Ansell
  ansell.stephen@mayo.edu

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Speaker)
  • 27.10., 10:30–12:00, Immunotherapy: Chances & Pitfalls (Speaker)
• Philippe Armand
  Philippe_Armand@dfci.harvard.edu

  • 27.10., 10:30–12:00, Immunotherapy: Chances & Pitfalls (Chair, Speaker)
  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Chair)
• Otavio Baiocchi
  obaiocchi@gmail.com

  • 28.10., 07:30–09:00, Interactive Case Discussion (Speaker)
• Christian Baues
  christian.baues@uk-koeln.de

  • 27.10., 08:45–10:15, Radiotherapy in Salvage (Speaker)
• Boris Böll
  boris.boell@uk-koeln.de

  • 27.10., 10:30–12:00, Challenges in older Lymphoma Patients (Speaker)
• Peter Borchmann
  peter.borchmann@uk-koeln.de

  • 28.10., 12:15–13:45, Tailoring sequencing and treatment targets (Chair, Speaker)
  • 28.10., 16:00–17:30, Focus on cHL: Current Insights and Future Perspectives (Chair, Speaker)
  • 29.10., 09:15–10:15, CAR T Cell Therapies: Hype Or Hope? (Speaker)
  • 29.10., 07:30–09:00, Advanced Stages (Speaker)
  • 29.10., 12:15–13:45, Checkpointblockade in Lymphomas (Speaker)
• Sven Borchmann
  sven.borchmann@uk-koeln.de

  • 28.10., 07:30–09:00, Interactive Case Discussion (Speaker)
  • 27.10., 10:30–12:00, Minimum Residual Disease (Speaker)
• Andreas Bräuninger
  andreas.braeuninger@patho.med.uni-giessen.de

  • 28.10., 10:30–12:00, Biology & Microenvironment (Abstract talk)
• Pauline Brice
  pauline.brice@sls.aphp.fr

  • 27.10., 10:30–12:00, Challenges in older Lymphoma Patients (Chair, Speaker)
• Paul J. Bröckelmann
  paul.broeckelmann@uk-koeln.de

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Speaker)
  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Abstract talk)
• Lieselot Buedts
  lieselot.buedts@kuleuven.be

  • 28.10., 10:30–12:00, Biology & Microenvironment (Poster pitch)
• Naike Casagrande
  naike.casagrande@libero.it

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Abstract talk)
• Olivier Casasnovas
  olivier.casasnovas@chu-dijon.fr

  • 29.10., 07:30–09:00, Advanced Stages (Speaker)
  • 27.10., 08:45–10:15, PET (Speaker)
• Luca Castagna
  luca.castagna@humanitas.it

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Abstract talk)
• Graham Collins
  Graham.Collins@ouh.nhs.uk

  • 28.10., 16:00–17:30, Focus on cHL: Current Insights and Future Perspectives (Speaker)
• Louis S. Constine
  louis_constine@urmc.rochester.edu

  • 27.10., 08:45–10:15, Radiotherapy in Salvage (Speaker)
• Annarosa Cuccaro
  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Abstract talk)
• David Cutter
  david.cutter@ndph.ox.ac.uk

  • 28.10., 14:00–15:30, Early Stages (Poster pitch)
• Bouthaina Dabaja
  bdabaja@mdanderson.org

  • 27.10., 08:45–10:15, Radiotherapy in Salvage (Speaker)
• Marie-Hélène Delfau-Larue
  marie-helene.delfau@hmn.aphp.fr.

  • 27.10., 10:30–12:00, Minimum Residual Disease (Speaker)
• Catherine Diefenbach
  catherine.diefenbach@nyumc.org

  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Poster pitch)
• Volker Diehl
  v.diehl@uni-koeln.de

  • 29.10., 07:30–09:00, Advanced Stages (Chair)
  • 27.10., 17:45–19:15, Opening Ceremony (Speaker)
• Markus Dietlein
  markus.dietlein@uk-koeln.de

  • 27.10., 08:45–10:15, PET (Chair)
• Theodor Dingermann
  Dingermann@em.uni-frankfurt.de

  • 27.10., 12:15–13:45, Biosimilar rituximab – a new treatment option (Speaker)
• Esther Drees
  e.drees@vumc.nl

  • 28.10., 10:30–12:00, Biology & Microenvironment (Abstract talk)
• Dennis Eichenauer
  dennis.eichenauer@uk-koeln.de

  • 28.10., 07:30–09:00, Interactive Case Discussion (Speaker)
  • 27.10., 12:15–13:45, Biosimilar rituximab – a new treatment option (Speaker)
• Hermann Einsele
  amocsari@celgene.com

  • 29.10., 09:15–10:15, CAR T Cell Therapies: Hype Or Hope? (Chair, Speaker)
• Andreas Engert
  a.engert@uni-koeln.de

  • 27.10., 12:15–13:45, Biosimilar rituximab – a new treatment option (Chair)
  • 28.10., 09:15–10:15, Oncology meets Autoimmunity (Chair)
  • 29.10., 12:15–13:45, Checkpointblockade in Lymphomas (Chair)
  • 29.10., 17:30–18:15, Closing Remarks (Chair, Speaker)
  • 28.10., 14:00–15:30, Early Stages (Speaker)
  • 27.10., 17:45–19:15, Opening Ceremony (Speaker)
• Andrew Evens
  ae378@cinj.rutgers.edu

  • 27.10., 10:30–12:00, Challenges in older Lymphoma Patients (Speaker)
  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Poster pitch)
• Valeria Fiaccadori
  valeria.fiaccadori.17@ucl.ac.uk

  • 28.10., 14:00–15:30, Early Stages (Abstract talk)
  • Award winner
• Alexander Fosså
  aff@ous-hf.no

  • 29.10., 07:30–09:00, Advanced Stages (Abstract talk)
• Jonathan Friedberg
  jonathan_friedberg@urmc.rochester.edu

  • 27.10., 10:30–12:00, Challenges in older Lymphoma Patients (Chair, Speaker)
  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Abstract talk)
• Andrea Gallamini
  sophie.ariano@takeda.com

  • 27.10., 08:45–10:15, PET (Speaker)
• Maher K. Gandhi
  m.gandhi@uq.edu.au

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Speaker)
• Stefan Gattenlöhner
  stefan.gattenloehner@patho.med.uni-giessen.de

  • 29.10., 10:30–12:00, Pediatric HL (Speaker)
• Jan Geissler
  jan@cmladvocates.net

  • 27.10., 17:45–19:15, Opening Ceremony (Speaker)
• Bertram Glaß
  bertram.glass@helios-gesundheit.de

  • 27.10., 12:15–13:45, Biosimilar rituximab – a new treatment option (Speaker)
• Ingrid Glimelius
  ingrid.glimelius@igp.uu.se

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Abstract talk)
  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Abstract talk)
• Manuel Gotti
  ma.gotti@smatteo.pv.it

  • 28.10., 14:00–15:30, Early Stages (Abstract talk)
• Catherine Guezennec
  catherine.guezennec@gmail.com

  • 29.10., 07:30–09:00, Advanced Stages (Abstract talk)
• Chul Ha
  hac@uthscsa.edu

  • 29.10., 07:30–09:00, Advanced Stages (Abstract talk)
• Anton Hagenbeek
  a.hagenbeek@amc.uva.nl

  • 27.10., 08:45–10:15, Developing Health Care Environments (Chair, Speaker)
  • 27.10., 10:30–12:00, Minimum Residual Disease (Chair, Speaker)
  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Speaker)
• Martin-Leo Hansmann
  m.l.hansmann@em.uni-frankfurt.de

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Chair)
• Sylvia Hartmann
  s.hartmann@em.uni-frankfurt.de

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Speaker)
• Jörg Henes
  joerg.henes@med.uni-tuebingen.de

  • 28.10., 09:15–10:15, Oncology meets Autoimmunity (Speaker)
• Oliver Henke
  oliver.henke@charite.de

  • 27.10., 08:45–10:15, Developing Health Care Environments (Chair, Speaker)
• Alex Herrera
  aherrera@coh.org

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Abstract talk)
• Mark Hertzberg
  mhertzberg10@gmail.com

  • 27.10., 16:00–17:30, Advanced HL: How Can We Do Better? (Chair, Speaker)
  • 28.10., 07:30–09:00, Interactive Case Discussion (Chair)
• Stefan Herzig
  tca.hanke@t-online.de

  • 27.10., 17:45–19:15, Opening Ceremony (Speaker)
• Richard Hoppe
  richard.hoppe@stanford.edu

  • 28.10., 14:00–15:30, Early Stages (Chair)
  • Award winner
• Martin Hutchings
  hutchings@dadlnet.dk

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Chair)
  • 27.10., 16:00–17:30, Advanced HL: How Can We Do Better? (Speaker)
• Tim Illidge
  tim.illidge@manchester.ac.uk

  • 27.10., 10:30–12:00, Immunotherapy: Chances & Pitfalls (Chair, Speaker)
  • 28.10., 14:00–15:30, Early Stages (Abstract talk)
• Peter Johnson
  johnsonp@soton.ac.uk

  • 29.10., 07:30–09:00, Advanced Stages (Chair)
• Justine Kahn
  jk2034@cumc.columbia.edu

  • 29.10., 10:30–12:00, Pediatric HL (Abstract talk)
  • Award winner
• Kristiina Karihtala
  kristiina.karihtala@gmail.com

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Abstract talk)
• Kara Kelly
  kara.kelly@roswellpark.org

  • 29.10., 10:30–12:00, Pediatric HL (Chair)
• Judith Kinley
  • 27.10., 08:45–10:15, Developing Health Care Environments (Speaker)
• Wolfram Klapper
  wklapper@path.uni-kiel.de

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Abstract talk)
• Hans Knoop
  hans.knoop@amc.uva.nl

  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Speaker)
• Carsten Kobe
  carsten.kobe@uk-koeln.de

  • 27.10., 08:45–10:15, PET (Speaker)
• Jan Kriz
  jan.kriz@ukmuenster.de

  • 28.10., 14:00–15:30, Early Stages (Poster pitch)
• Ralf Küppers
  ralf.kueppers@uk-essen.de

  • 28.10., 10:30–12:00, Biology & Microenvironment (Speaker)
  • Award winner
• Andrew Lister
  a.lister@qmul.ac.uk

  • 28.10., 07:30–09:00, Interactive Case Discussion (Chair)
• Anna Lollies
  anna.lollies@uk-essen.de

  • 28.10., 10:30–12:00, Biology & Microenvironment (Abstract talk)
• Ryan Lynch
  rclynch@uw.edu

  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Abstract talk)
  • Award winner
• Maja Maraldo
  maja.vestmoe.maraldo@regionh.dk

  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Abstract talk)
  • 29.10., 10:30–12:00, Pediatric HL (Abstract talk)
• Simone Marnitz-Schulze
  simone.marnitz-schulze@uk-koeln.de

  • 27.10., 08:45–10:15, Radiotherapy in Salvage (Chair, Speaker)
• Carmen Martinez
  Yolanda.Serrano@takeda.com

  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Abstract talk)
• Christine Mauz-Körholz
  Christine.Mauz-Koerholz@paediat.med.uni-giessen.de

  • 29.10., 10:30–12:00, Pediatric HL (Chair)
• Michel Meignan
  michel.meignan@hmn.aphp.fr

  • 27.10., 08:45–10:15, PET (Chair)
• Monika Metzger
  Monika.Metzger@STJUDE.ORG

  • 29.10., 10:30–12:00, Pediatric HL (Abstract talk)
• Daniel Molin
  daniel.molin@igp.uu.se

  • 28.10., 12:15–13:45, Tailoring sequencing and treatment targets (Speaker)
• Lindsay Morton
  mortonli@mail.nih.gov

  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Speaker)
  • 27.10., 10:30–12:00, Survivorship (Speaker)
• Craig H. Moskowitz
  CHM78@miami.edu

  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Chair, Abstract talk)
  • 27.10., 16:00–17:30, Advanced HL: How Can We Do Better? (Speaker)
• Anja Mottok
  anja.mottok@uni-ulm.de

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Speaker)
• Susan Parsons
  sparsons@tuftsmedicalcenter.org

  • 29.10., 10:30–12:00, Pediatric HL (Speaker)
• Ewa Paszkiewicz-kozik
  joanna.obal@takeda.com

  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Abstract talk)
• Astrid Pavlovsky
  astridp@intramed.net

  • 27.10., 16:00–17:30, Advanced HL: How Can We Do Better? (Speaker)
• Michiel Pegtel
  d.pegtel@vumc.nl

  • 27.10., 10:30–12:00, Minimum Residual Disease (Speaker)
• Ananda Plate
  plate@mpeurope.org

  • 27.10., 10:30–12:00, Survivorship (Chair)
  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Chair)
• John Radford
  John.Radford@manchester.ac.uk

  • 29.10., 07:30–09:00, Advanced Stages (Speaker)
• John Raemaekers
  J.Raemaekers@hemat.umcn.nl

  • 28.10., 14:00–15:30, Early Stages (Chair)
• George Rassidakis
  georgios.rassidakis@ki.se

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Abstract talk)
• Joanna Romejko-Jarosinska
  joanna.romejko-jarosinska@coi.pl

  • 28.10., 07:30–09:00, Interactive Case Discussion (Speaker)
• Mark Roschewski
  mark.roschewski@nih.gov

  • 27.10., 10:30–12:00, Minimum Residual Disease (Speaker)
• Andreas Rosenwald
  rosenwald@uni-wuerzburg.de

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Chair)
• Davide Rossi
  davide.rossi@ior.iosi.ch

  • 28.10., 10:30–12:00, Biology & Microenvironment (Speaker)
• Bianca Schuhmacher
  b.schuhmacher@em.uni-frankfurt.de

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Speaker)
• Cindy Schwartz
  cschwartz@mcw.edu

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Poster pitch)
• Margaret Shipp
  Margaret_Shipp@dfci.harvard.edu

  • 27.10., 14:00–15:30, Immunotherapy – Biomechanisms (Chair, Speaker)
  • 28.10., 16:00–17:30, Focus on cHL: Current Insights and Future Perspectives (Speaker)
• Yuqin Song
  songyuqin622@163.com

  • 29.10., 14:00–15:30, Immunotherapy – Clinical (Abstract talk)
• Lena Specht
  specht@rh.dk

  • 27.10., 08:45–10:15, Radiotherapy in Salvage (Speaker)
• Nele Stadtbäumer
  nele.stadtbaeumer@rwth-aachen.de

  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Poster pitch)
  • Award winner
• Christian Steidl
  CSteidl@bccancer.bc.ca

  • 27.10., 08:45–10:15, Molecular Pathogenesis (Chair)
  • 28.10., 10:30–12:00, Biology & Microenvironment (Chair)
• Anna Sureda
  asureda@iconcologia.net

  • 29.10., 16:00–17:30, Relapsed/Refractory HL (Chair, Poster pitch)
  • 28.10., 12:15–13:45, Tailoring sequencing and treatment targets (Speaker)
• Simone Thomas
  amocsari@celgene.com

  • 29.10., 09:15–10:15, CAR T Cell Therapies: Hype Or Hope? (Speaker)
• Maria Alejandra Torres Viera
  matorresviera@gmail.com

  • 27.10., 08:45–10:15, Developing Health Care Environments (Speaker)
• Alessandra Tucci
  alessandra.tucci@asst-spedalicivili.it

  • 27.10., 10:30–12:00, Challenges in older Lymphoma Patients (Speaker)
• Anke van den Berg
  a.van.den.berg01@umcg.nl

  • 28.10., 10:30–12:00, Biology & Microenvironment (Chair)
• Flora van Leeuwen
  f.v.leeuwen@nki.nl

  • 27.10., 10:30–12:00, Survivorship (Chair, Speaker)
  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Chair)
• Andrea Visentin
  • 27.10., 08:45–10:15, Molecular Pathogenesis (Abstract talk)
• Lorna Warwick
  • 28.10., 17:45–19:15, Survivorship & Patients’ Perspective (Speaker)
• Annika Weiß
  annika.weiss@stud.uni-due.de

  • 28.10., 10:30–12:00, Biology & Microenvironment (Poster pitch)
  • Award winner
• Catharine West
  catharine.west@manchester.ac.uk

  • 27.10., 10:30–12:00, Survivorship (Speaker)
• Leszek Wojnowski
  wojnowski@uni-mainz.de

  • 27.10., 10:30–12:00, Survivorship (Speaker)
• Dominik Wolf
  dominik.wolf@ukb.uni-bonn.de

  • 29.10., 12:15–13:45, Checkpointblockade in Lymphomas (Speaker)
• Daniel Wolff
  daniel.wolff@ukr.de

  • 28.10., 09:15–10:15, Oncology meets Autoimmunity (Speaker)
• Joachim Yahalom
  yahalomj@mskcc.org

  • 27.10., 08:45–10:15, Radiotherapy in Salvage (Chair, Speaker)
• Joanna Yang
  joanna.yang@ucsf.edu

  • 28.10., 14:00–15:30, Early Stages (Abstract talk)
• Jun Yang
  Jun.Yang@STJUDE.ORG

  • 29.10., 10:30–12:00, Pediatric HL (Speaker)
• Pier Luigi Zinzani
  pierluigi.zinzani@unibo.it

  • 27.10., 10:30–12:00, Minimum Residual Disease (Chair, Speaker)
  • 29.10., 12:15–13:45, Checkpointblockade in Lymphomas (Speaker)

Allocations

• Kleiner Saal

  Workshops, Get Together, Poster Walk

• Marsilius Saal

  Workshop

Allocations

• Weinkeller

Allocations

• Großer Saal

  Main Program, Satellite Symposia, Workshop

• Isabellensaal

  Workshops, Exhibition

Allocations

• Martin & Augustin

Selected for Oral Presentation

• T004 (0051) Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin lymphoma

  • Ingrid Glimelius
  • Rose-Marie Amini
  • Beatrice Ginman
  • Daniel Molin
  • Gunilla Enblad
  • Peter Hollander

• T005 (0077) Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc

  • Naike Casagrande
  • Cinzia Borghese
  • Elena Mariotto
  • Cristina Vicenzetto
  • Andrea Favero
  • Donatella Aldinucci
  • CB and NC cofirst Authors

• T006 (0079) The peripheral blood Neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis

  • A.Cuccaro
  • I.Zangrilli
  • F.Corrente
  • E.Cupelli
  • F.Fatone
  • E.Galli
  • E.Maiolo
  • S.Annunziata
  • V.Rufini
  • M.Balducci
  • F.D'Alò
  • S.Bellesi
  • V.De Stefano
  • S.Hohaus

• T007 (0099) PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin lymphoma

  • Kristiina Karihtala
  • Suvi-Katri Leivonen
  • Teijo Pellinen
  • Oscar Brück
  • Marja-Liisa Karjalainen-Lindsberg
  • Satu Mustjoki
  • and Sirpa Leppä

Selected for Poster Pitch

• P002 (0061) Development of an α-CD30 Bispecific Antibody Immunotherapy for Hodgkin Lymphoma

  • Schwartz
  • Cindy L
  • Oldham
  • Robyn AA
  • Faber
  • Mary L
  • Thakur A
  • Lum
  • Lawrence G
  • Medin
  • Jeffrey A

Posters

• P001 (0015) Hodgkin‘s Variant of Richter Transformation in the Czech Republic

  • Mociková H
  • Sýkorová A
  • Marková J
  • Klásková K
  • Šimkovič M.
  • Smolej L
  • Kalinová M
  • Campr V
  • Kozák T
  • on behalf of the Czech Hodgkin Lymphoma Study Group

• P003 (0157) Microsatellite and chromosomal instability constitute two mechanisms that independently lead to genomic instability in Hodgkin lymphoma.

  • Radhia M’Kacher
  • Corina Cuceu
  • Bruno Colicchio
  • Steffen Junker
  • François Plassa
  • Justyna Mika
  • Monika Frenzel
  • Mustafa AL Jawhari
  • William M. Hempel
  • Grainne O’Brien
  • Luc Morat
  • Theodore Girinsky
  • Alain Dieterlen
  • Joanna Polanska
  • Christophe Badie
  • Eric Jeandidier
  • Patrice Carde

Selected for Oral Presentation

• T001 (0006) CK2A is overexpressed, active and targetable with silmitasertib In classical Hodgkin Lymphoma

  • Visentin A.
  • Frezzato F.
  • Severin F.
  • Pizzi M.
  • Martini V.
  • Raggi F.
  • Imbergamo S
  • Scomazzon E
  • Pravato S
  • Manni S.
  • Facco M.
  • Carlo-Stella C.
  • Semenzato G.
  • Piazza F.
  • Trentin L.

• T002 (0076) Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma

  • Ron D. Jachimowicz
  • Luise Pieper
  • Artur Gontarewicz
  • Annette Plütschow
  • Heinz Haverkamp
  • Sarah Reinke
  • Christoph Thorns
  • Martin Leo Hansmann
  • Peter Möller
  • Andreas Rosenwald
  • Harald Stein
  • Christian Kohler
  • Gunther Glehr
  • H. Christian Reinhardt
  • Peter Borchmann
  • Bastian v. Tresckow
  • Michael Altenbuchinger
  • Rainer Spang
  • Andreas Engert
  • Wolfram Klapper

• T003 (0171) ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma

  • Louloudenia Velentza
  • Ioannis Zerdes
  • Amir Hossein Danesh Manesh
  • Nikolaos Tsesmetzis
  • Mohammad Hojat-Farsangi
  • Amineh Ghaderi
  • Elias Drakos
  • Marzia Palma
  • Anders Österborg
  • Håkan Mellstedt
  • George Z. Rassidakis

• T008 (0050) Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma patients to determine pathogenic mechanisms and monitor therapy

  • Andreas Bräuninger
  • Ann-Kathrin Desch
  • Kristin Kunze
  • Ante Boten
  • Alexander Brobeil
  • Mathias Rummel
  • Lars Kurch
  • Thomas Georgi
  • Regine Kluge
  • Christine Mauz-Körholz
  • Dieter Körholz
  • Stefan Gattenlöhner

• T009 (0083) Circulating Tumor DNA as a Biomarker for the Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma

  • Michael C. Jin
  • David M Kurtz
  • Mohammad Shahrokh Esfahani
  • Brian J. Sworder
  • Joseph Schroer-Martin
  • Joanne Soo
  • Cynthia Glover
  • Mark Roschewski
  • Wyndham Wilson
  • Ulrich Düehrsen
  • Andreas Hüttmann
  • Davide Rossi
  • Gianluca Gaidano
  • Jason Westin
  • Maximilian Diehn
  • Ranjana Advani
  • Ash A. Alizadeh

• T010 (0113) Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin lymphoma patients

  • E.E.E. Drees
  • M.A.J. van Eijndhoven
  • I. Ciocanea-Teodorescu
  • N.J. Groenewegen
  • L.I. Prins
  • X. Tran
  • A. Valles
  • D. Koppers-Lalic
  • E. Aparicio
  • M. Hackenberg
  • D. de Jong
  • J.M. Zijlstra
  • and D.M. Pegtel

• T011 (0162) Molecular Mechanisms in the Pathogenesis of Composite Lymphomas

  • Anna Lollies
  • Markus Schneider
  • Sylvia Hartmann
  • Stephan Mathas
  • Enrico Tiacci
  • Marc Andree Weniger
  • Patricia Johansson
  • Jan Dürig
  • Ludger Klein-Hitpass
  • Martin-Leo Hansmann and Ralf Küppers

Selected for Poster Pitch

• P019 (0158) Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout

  • Annika L. Weiß
  • Anna Lollies
  • Freya Kretzmer
  • Marc A. Weniger
  • Ralf Küppers

• P021 (0168) Copy number aberrations in cell-free DNA of Hodgkin lymphoma

  • Lieselot Buedts
  • Thomas Tousseyn
  • Olivier Gheysens
  • Julio Finalet-Ferreiro
  • Luc Dehaspe
  • Gregor Verhoef
  • Sanne Smits
  • Joris Vermeesch
  • Peter Vandenberghe

Posters

• P004 (0011) Array-based DNA methylome analyses of classical Hodgkin lymphoma

  • Vogt J.
  • Kretzmer H.
  • Ammerpohl O.
  • Vallés Uriate L.
  • Drexler HG.
  • Wagener R.
  • López C.
  • Siebert R.

• P005 (0036) The role of TCF3 in classical Hodgkin lymphoma

  • Rianne Veenstra
  • Joost Kluiver
  • Lydia Visser
  • Arjan Diepstra and Anke van den Berg

• P006 (0037) Recurrent exportin 1 mutations in patients with classical Hodgkin Lymphoma

  • Almudena Navarro-Bailón
  • Cristina Jiménez
  • Sara Alonso-Álvarez
  • Alicia Antón
  • María Carmen Chillón
  • Miguel Alcoceba
  • María García-Álvarez
  • Isabel Prieto
  • Alejandro Medina
  • Verónica González-de-la-Calle
  • Marcos González
  • María Eugenia Sarasquete
  • Ramón García-Sanz

• P007 (0043) TARC immunohistochemistry in the diagnosis of classical Hodgkin lymphoma

  • Carlijn Veldman
  • Stefano Rosati
  • Anke van den Berg
  • Lydia Visser
  • Wouter Plattel
  • and Arjan Diepstra

• P008 (0053) Whole-slide-image analysis of the tumormicronenvironment in classical Hodgkin Lymphoma

  • Luise Pieper
  • Sarah Reinke
  • Ron Jachimowicz
  • Annette Plütschow
  • Andreas Engert
  • Wolfram Klapper

• P009 (0069) CD2 is an important adhesion molecule in the initial interaction between Hodgkin Reed-Sternberg cells and rosetting T cells

  • J. Veldman
  • A. van den Berg
  • L. Visser
  • A. Diepstra

• P010 (0073) A new reliable and highly specific antibody to detect SOCS1 (Silencer of Cytokine Signaling 1).

  • Stephanie E. Weissinger
  • Malena Zahn
  • Kevin Mellert
  • Ralf Marienfeld
  • Gerhard Moldenhauer
  • Peter Möller.

• P012 (0081) Soluble cytokines in Hodgkin lymphoma patients treated with a GHSG policy: an analysis of the Czech Hodgkin Lymphoma Study Group

  • Vit Prochazka
  • Marie Lukasova
  • Eva Kriegova
  • Alice Sykorova
  • Heidi Mocikova
  • Tomas Papajik
  • David Belada
  • Jana Markova
  • Katerina Klaskova
  • Veronika Hanackova
  • Gabriela Gabcova
  • Zuzana Mikulková
  • and Pavla Stepankova
  • on behalf of the Czech Hodgkin Lymphoma Study Group

• P013 (0088) Digital image analysis of the microenvironment in classical Hodgkin lymphoma comparing primary tumor and relapse

  • Franziska Jochims¹
  • Sarah Kretschmer¹
  • Ron Jachimowicz²'³
  • Falko Fend⁴
  • German Ott⁵
  • Martin-Leo Hansmann⁶
  • Christoph Thorns⁷
  • Annette Plütschow³
  • Andreas Engert²'³
  • Wolfram Klapper¹

• P014 (0098) CD47 is expressed on Hodgkin Reed Sternberg cells in Classical Hodgkin lymphoma.

  • Alonso
  • Lopez-Pereira B
  • Corte
  • Alonso-Alvarez S
  • Fernandez-Vega I
  • García-Moro MA
  • Bernal
  • Alonso-Arias R
  • and Colado E

• P015 (0100) Characterization of T-cell phenotypes with clinical significance in patients with classical Hodgkin lymphoma

  • Kristiina Karihtala
  • Suvi-Katri Leivonen
  • Teijo Pellinen
  • Oscar Brück
  • Marja-Liisa Karjalainen-Lindsberg
  • Satu Mustjoki
  • and Sirpa Leppä

• P016 (0104) Phenotypic characterization of circulating T and NK cells in Hodgkin lymphoma patients in relation to tumor burden and treatment

  • Tom A. Mulder
  • Kia Heimersson
  • Barbro Näsman-Glaser
  • Lotta Hansson
  • and Marzia Palma

• P017 (0120) Immunologic Biomarkers of Response and Resistance to Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

  • Joo Y. Song
  • Wing C. Chan
  • Charles Warden
  • Xiwei Wu
  • Dennis D. Weisenburger
  • Robert Chen
  • Alex F. Herrera

• P018 (0139) GATA3 expression distinguishes Classic Hodgkin lymphoma from Nodular lymphocyte Hodgkin lymphoma

  • Sridhar Epari
  • Vidya R
  • Hasmukh Jain#
  • Bhausaheb Bagal#
  • Siddharth Laskar
  • Manju Sengar#
  • Sumeet Gujral and Tanuja Shet

• P020 (0164) Extracellular ciruculating DNA in Hodgkins lymphoma patients: biological corellates and prognostic impact

  • Dino Dujmović
  • Sandra Bašić Kinda
  • Ivo Radman
  • Goran Lauc
  • Ivana Ilić
  • Igor Aurer

• P022 (0170) The Tumor Suppressor SAMHD1 is Downregulated by MYC in Classical Hodgkin Lymphoma

  • Ioanna Xagoraris
  • Theodoros Vassilakopoulos
  • PhD
  • Nikolas Herold
  • Nikolaos Tsesmetzis
  • MSc.
  • Joseph Khoury
  • Elias Drakos
  • and George Rassidakis

• P031 (0145) Evaluation of CCL17 (TARC) as a diagnostic biomarker for classical Hodgkin lymphoma: interim results from the CANDEL study.

  • Annette Lake
  • Iain J Nixon
  • Paula Beattie
  • Kim Ah-See
  • Dominic Culligan
  • Nicholas Heaney
  • Pam McKay
  • Omar J Hilmi
  • and Ruth F Jarrett

Selected for Oral Presentation

• T012 (0066) Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial

  • Valeria Fiaccadori
  • Anouk Neven
  • Anne-Claire Gac
  • Luigi Rigacci
  • Theo Girinsky
  • Michel Meignan
  • Martin Hutchings
  • Annibale Versari
  • Oumedaly Reman
  • Umberto Ricardi
  • Marc Andre
  • Massimo Federico
  • John Raemaekers
  • Catherine Fortpied

• T013 (0095) Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin lymphoma in the UK NCRI RAPID trial

  • Tim Illidge
  • Elizabeth Phillips
  • Nicholas Counsell
  • Ruth Pettengell
  • Peter Johnson
  • Dominic Culligan
  • Bilyana Popova
  • Laura Clifton-Hadley
  • Andrew McMillan
  • Peter Hoskin
  • Sally Barrington
  • John Radford

• T014 (0118) Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era

  • Manuel Gotti
  • Roberta Sciarra
  • Alessandro Pulsoni
  • Francesco Merli
  • Chiara Rusconi
  • Barbara Botto
  • Alessandro Re
  • Andrea Rossi
  • Luigi Rigacci
  • Alberto Fabbri
  • Marina Liberati
  • Michele Merli
  • Luca Nassi
  • Carmelo Carlo Stella
  • Maurizio Bonfichi
  • Valentina Zoboli
  • Germana Tartaglia
  • Isabel Alvarez
  • Erika Meli
  • Maura Nicolosi
  • Daniela Dalceggio
  • Silvia Ferrari
  • Benedetta Puccini
  • Emanuele Cencini
  • Viviana Apoll

• T015 (0124) Brentuximab Vedotin and AVD Chemotherapy followed by Reduced Dose/Volume Radiotherapy in Patients with Early Stage, Unfavorable Hodgkin Lymphoma

  • Joanna C. Yang
  • Anita Kumar
  • Carla Casulo
  • Ranjana Advani
  • Elizabeth Budde
  • Paul M. Barr
  • Connie L. Batlevi
  • Philip Caron
  • Robert Chen
  • Louis S. Constine
  • Amanda Courtien
  • Savita V. Dandapani
  • Pamela Drullinsky
  • Jonathan W. Friedberg
  • Audrey Hamilton
  • Paul A. Hamlin
  • Richard T. Hoppe
  • Steven M. Horwitz
  • Andrew Intlekofer
  • Oscar Lahoud
  • Matthew J. Matasar
  • Alison J. Moskowitz
  • Ariela Noy
  • Maria L. Palomba
  • Carol S. Portlock
  • Heiko Schöder
  • David J. Straus
  • Santosh Vardhana
  • Shreya

Selected for Poster Pitch

• P027 (0101) Cardiovascular Radiation Dosimetry and Predicted Cardiovascular Risks from Involved Field Radiotherapy within the UK ‘RAPID’ Trial in Early Low-Risk Hodgkin Lymphoma

  • Dr David J. Cutter
  • MD DPhil
  • Dr Johanna Ramroth
  • DPhil
  • Patricia Diez
  • MSc
  • Andy Buckle
  • David Kennedy
  • Bilyana Popova
  • Laura Clifton-Hadley
  • PhD
  • Prof Tim Illidge
  • MD PhD
  • Prof Sarah C. Darby
  • Prof John Radford

• P029 (0142) Quality Assurance of Involved-Node Radiotherapy: First Results of the HD17-Trial of the GHSG

  • Kriz J
  • Baues C
  • Oertel M
  • Engenhart-Cabillic R
  • Herfarth K
  • Lukas P
  • Marnitz-Schulze S
  • Schmidberger H
  • Vordermark D
  • Haverkamp U
  • Engert A
  • Eich HT

Posters

• P023 (0003) Conventional vs multifractionation at radiotherapy for above diaphragm stage II Hodgkin Lymphoma: 30-year experience of single Center

  • Ilyin N. V.
  • Vinogradova J. N.
  • Ivanova E. I.

• P024 (0009) Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity

  • David J. Straus
  • M.D.

• P025 (0033) Metabolic tumor volume by positron emission tomography ⁄ computed tomography for deciding the therapeutic modality in patients with early stage Hodgkin’s lymphoma

  • Joo-Seop Chung
  • Moo-Gon Song
  • Do-Young Kim
  • Ho-Jin Shin
  • Seong-Jang Kim
  • Young-Don Joo

• P026 (0057) Interim- PET Results for Prognosis in Adults with Hodgkin Lymphoma: A Prognostic Factor Exemplar Review (Preliminary Results)

  • Angela Aldin
  • Marialena Trivella
  • Lise J Estcourt
  • Gary Collins
  • Karel Moons
  • Andreas Engert
  • Bastian von Tresckow
  • Carsten Kobe
  • Farid Foroutan
  • Nina Kreuzberger
  • Nicole Skoetz

• P028 (0102) Patterns of Relapse in Patients Treated for Early Stage Classical Hodgkin Lymphoma in the Modern Era

  • Karin Nielsen MD
  • Maja V. Maraldo MD
  • PhD
  • Anne Kiil Berthelsen MD
  • Annika Loft MD
  • Peter Meidahl Petersen MD
  • Marianne C. Aznar
  • Ivan Richter Vogelius
  • DMSc
  • Peter Brown
  • Lena Specht MD

• P030 (0143) Once-a-cycle vs. daily G-CSF in early-unfavorable stages of Hodgkin Lymphoma treated with BEACOPP escalated followed by ABVD

  • Michael Fuchs
  • Horst Müller
  • Dennis A. Eichenauer
  • Stefanie Kreissl
  • Andreas Engert
  • and Peter Borchmann

• P050 (0075) Clinical Characteristics and Prognosis Analysis of Early-Stage Classical Hodgkin Lymphoma

  • Jun Zhu M.D. PhD.
  • Yan-fei Liu M.D.
  • Meng Wu M.D.
  • Mingzi Yang M.D.
  • Aliya M.D.
  • Reyizha Rnuersulitan M.D.
  • Yuqin Song M.D.

Selected for Oral Presentation

• T016 (0018) Employment situation among long-term Hodgkin lymphoma survivors in Europe: An analysis of patients from nine consecutive EORTC-LYSA trials

  • Maja V. Maraldo
  • Michal Kicinski
  • Marleen A.E. van der Kaaij
  • Francesco Giusti
  • Paul Meijnders
  • Berthe M.P. Aleman
  • John M.M. Raemaekers
  • Elisabeth C. Moser
  • Hanneke C. Kluin-Nelemans
  • Michele Spina
  • Christophe Fermé
  • Pauline Brice
  • Olivier Casasnovas
  • Aspasia Stamatoullas
  • Marc André
  • Fabien Le Bras
  • Catherine Fortpied
  • Jan Bogaerts
  • Michel Henry-Amar
  • & Lifang Liu

• T017 (0044) Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin lymphoma in first remission?

  • Lynch RC
  • Sundaram V
  • Desai M
  • Henry S
  • Wood D
  • Daadi SE
  • Corbelli K
  • Rosenberg SA
  • Hoppe RT
  • Advani RH

• T018 (0140) Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators

  • Caroline E. Weibull
  • Anna L.V. Johansson
  • Sandra Eloranta
  • Karin E. Smedby
  • Magnus Björkholm
  • Paul C. Lambert
  • Paul W. Dickman
  • Ingrid Glimelius

Selected for Poster Pitch

• P036 (0023) Early-Stage Hodgkin Lymphoma (HL) in the Modern Era: Harnessing Simulation Modeling to Delineate Long-Term Patient Outcomes

  • Susan K. Parsons
  • Michael J. Kelly
  • Joshua T. Cohen
  • Sharon M. Castellino
  • Tara O. Henderson
  • Kara M. Kelly
  • Frank G. Keller
  • Tobi J. Henzer
  • Anita J. Kumar
  • Peter Johnson
  • Ralph M. Meyer
  • John Radford
  • John Raemaekers
  • David C. Hodgson
  • Andrew M. Evens

• P060 (0122) The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma

  • A. Mayer
  • N. Stadtbäumer
  • S. Kreissl
  • H. Müller
  • H. Görgen
  • P. Borchmann

Posters

• P032 (0002) Audit of lymphoma patient group irradiated blood product policy compliance at a UK comprehensive cancer centre

  • Jane Gibson
  • Sarah Wells
  • Sharon Jackson
  • Philip Higham
  • Deborah Seal
  • Kim Linton

• P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET

  • Visentin A
  • Pravato S
  • Scomazzon E
  • Imbergamo S
  • Branca A
  • Gregianin M
  • Vio S
  • Boso C
  • Piazza F
  • Vianello F
  • Zambello R
  • Semenzato G
  • Trentin L

• P034 (0021) Returning to school or work after Hodgkin lymphoma: An EORTC-LYSA cross-sectional study

  • Maja V. Maraldo
  • Michal Kicinski
  • Marleen A.E. van der Kaaij
  • Francesco Giusti
  • Paul Meijnders
  • Berthe M.P. Aleman
  • John M.M. Raemaekers
  • Elisabeth C. Moser
  • Hanneke C. Kluin-Nelemans
  • Michele Spina
  • Christophe Fermé
  • Pauline Brice
  • Olivier Casasnovas
  • Aspasia Stamatoullas
  • Marc André
  • Fabien Le Bras
  • Catherine Fortpied
  • Jan Bogaerts
  • Michel Henry-Amar
  • & Lifang Liu

• P035 (0022) Fatigue impairment in Hodgkin and non-Hodgkin lymphoma survivors: A joint EORTC-LYSA cross-sectional survey

  • Nicolas Mounier
  • Raphaël Busson
  • Marleen van der Kaaij
  • Catherine Thieblemont
  • Berthe Aleman
  • Aspasia Stamatoullas
  • John Raemaekers
  • Vincent Ribrag
  • Michele Spina
  • Hervé Tilly
  • Christophe Fermé
  • Corinne Haioun
  • René-Olivier Casasnovas
  • Hanneke Kluin-Nelemans
  • Michel Henry-Amar

• P037 (0027) The pathway to diagnosis of Hodgkin Lymphoma in South Africa: the determinants and impact of diagnostic delay

  • Antel K
  • Levetan C
  • Mohamed Z
  • Louw VJ
  • Oosthuizen J
  • Verburgh E

• P038 (0029) Hepatitis B virus infection is not associated with poor prognosis in Hodgkin lymphoma patients: A case-control study

  • Weiping Liu
  • Mingzi Yang
  • Meng Wu
  • Lingyan Ping
  • Yuqin Song
  • Jun Zhu

• P039 (0030) Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients

  • Caroline E. Weibull
  • Magnus Björkholm
  • Ingrid Glimelius
  • Paul C. Lambert
  • Therese M. L. Andersson
  • Karin E. Smedby
  • Paul W. Dickman
  • Sandra Eloranta

• P040 (0031) Clinicopathological features and prognosis of 387 cases with classical Hodgkin lymphoma from China

  • Jun Zhu
  • Mingzi Yang
  • Meng Wu
  • Lingyan Ping
  • Aliya
  • Yanfei Liu
  • Reyizha Nuersulitan
  • Yuqin Song

• P041 (0034) A study of patient and general practitioner (GP) views and experience of managed local follow-up of long term lymphoma survivors (ADAPT)

  • Sally Taylor
  • Valerie Goode
  • Ellie White
  • Richard Cowan
  • Janelle Yorke
  • John Radford

• P042 (0035) Anemia has a negative impact on the outcome of patients with Hodgkin lymphoma

  • Weiping Liu
  • Mingzi Yang
  • Meng Wu
  • Lingyan Ping
  • Xiaopei Wang
  • Yuqin Song
  • Jun Zhu

• P043 (0039) Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: A retrospective study of 27 cases

  • Jun Zhu
  • Mingzi Yang
  • Meng Wu
  • Lingyan Ping
  • Aliya
  • Yanfei Liu
  • Reyizha Nuersulitan
  • Yuqin Song

• P044 (0046) Investigation the role of adding a serum biomarker to interim PET/CT in Hodgkin lymphoma patients

  • Ádám Jóna
  • Kata Husi
  • Béla Nagy
  • Zsolt Fejes
  • Zsófia Miltényi
  • Árpád Illés

• P045 (0047) Hyperlipoproteinemia and markers of atherosclerosis progression in long-term survivors of Hodgkin lymphoma in childhood or adolescence and in healthy controls

  • Cepelova M.
  • Kruseova J.
  • Luks A.
  • Cepela P.
  • Potockova J.
  • Kraml P.

• P046 (0052) No clinical signals of Drug – Drug interaction of NEPA (netupitant + palonosetron) in cHL patients receiving ABVD regimen: a single-center real life experience

  • Vittorio Ruggero Zilioli
  • Periana Minga
  • Lara Crucitti
  • Erika Meli
  • Chiara Rusconi
  • Roberto Cairoli

• P047 (0058) An Epidemiological Study of Hodgkins Lymphoma from a single tertiary care centre in India with study of disease outcome

  • Dr. Ankita Sen
  • Dr. T.K. Dolai
  • Dr. S.N. Baul
  • Dr. P.K. Mandal
  • Dr. R. De
  • Dr. S. Dutta
  • Dr. P. Chakrabarti

• P048 (0065) Mature oocytes cryopreservation: a feasible fertility preservation technique in adult Hodgkin lymphoma female patients.

  • Viviani S
  • Somigliana E
  • Filippi F
  • Landi F
  • Paffoni A
  • Mangili G
  • Mazza R
  • Papaleo E
  • Sigismondi C
  • Devizzi L
  • Dodero A
  • Farina L
  • Corradini P

• P049 (0072) Results of cardiovascular screening in the BETER survivorship care initiative for Hodgkin lymphoma

  • S.R. Pereboom
  • A. Nijdam
  • B.M.P. Aleman
  • R.W.M. van der Maazen
  • J.M. Zijlstra
  • R.J. de Weijer
  • M.B. van ’t Veer
  • J.M.M. Raemaekers
  • F.E. van Leeuwen
  • on behalf of the BETER consortium

• P051 (0080) Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin lymphoma

  • Berthe M.P. Aleman
  • PhD
  • Inge M. Krul
  • MSc
  • Annemieke W.J. Opstal – van Winden
  • Cécile P.M. Janus
  • Laurien A. Daniëls
  • Y. Appelman
  • Angela H.E.M. Maas
  • Frederika A. van Nimwegen
  • Simone de Vries
  • Michael Hauptmann
  • Katarzyna Jóźwiak
  • and Flora E. van Leeuwen

• P052 (0082) Combined prognostic role of biomarkers and PET/CT in patients with Hodgkin lymphoma

  • Kata Husi
  • Árpád Illés
  • Béla Nagy
  • Zsolt Fejes
  • Judit Bedekovics
  • Zsófia Miltényi

• P053 (0091) NEUTROPHIL TO LYMPHOCITE RATIO PREDICTS OVERALL SURVIVAL IN NEWLY DIAGNOSED HODGKIN LYMPHOMA PATIENTS - SINGLE CENTRE EXPERIENCE

  • Jelena Hajder
  • Natasa Stanisavljević
  • Dragomir Marisavljević
  • Vladimir Jurišić
  • Olivera Marković
  • Radmila Zivković

• P054 (0092) Pregnancy in patients in complete remission after Hodgkin Lymphoma: clinical features and outcome.

  • Francesco Gaudio
  • Claudia Nardelli
  • Tommasina Perrone
  • Filomena Emanuela Laddaga
  • Giorgina Specchia

• P055 (0096) Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)

  • Angie Mae Rodday
  • PhD
  • Susan K Parsons
  • MRP
  • Rizvan Bush
  • Qinglin Pei
  • Rachael Curtis
  • Frank Keller
  • Kara Kelly
  • Tara Henderson
  • MPH
  • Sharon M Castellino
  • MSc

• P056 (0097) Cognitive Dysfunction after Treatment for Hodgkin lymphoma

  • Ferenc Magyari
  • Tibor Ivánka
  • Anikó Égerházi
  • Zsófia Simon
  • Zsófia Miltényi
  • Karolina Kósa
  • Árpád Illés

• P057 (0108) Cognitive impairments in patients with Hodgkin’s Lymphoma

  • Vinokurova E.G.
  • Marchenko A.A.
  • Khrushchev S.O.
  • Olexenko L.V.
  • Rupchev G.E.
  • Vybornykh D.E.
  • Moiseeva T.N.

• P058 (0109) Fertility in Hodgkin´s lymphoma patients after initial therapy at Santa Casa de São Paulo Medical School

  • Maria Fernanda Evangelista Simões
  • Gilnara Fontinelle Silva
  • Thaís Rodrigues da Cunha Fischer
  • Carlos Sérgio Chiattone
  • Sergio Costa Fortier
  • Talita Máira Bueno da Silveira da Rocha

• P059 (0114) AA Amyloidosis Causing Nephrotic Syndrome in Two Patients with Hodgkin Lymphoma

  • Ayse Salihoglu
  • Tugrul Elverdi
  • Dilek Keskin
  • Ahmet Emre Eskazan
  • Muhlis Cem Ar
  • Seniz Ongoren
  • Nukhet Tuzuner
  • Teoman Soysal
  • Zafer Baslar

• P061 (0125) Chemotherapy-induced polyneuropathy in patients with Hodgkin lymphoma treated with vinca-alkaloids

  • Smardova L
  • Vlckova E
  • Rajdova A
  • Raputova J
  • Bednarik J
  • Kral Z

• P062 (0134) Long term health care use in relapsed and non-relapsed paediatric and young adult Hodgkin lymphoma patients – a population-based cohort study from Sweden and Denmark

  • Ingrid Glimelius
  • Annika Englund
  • Klaus Rostgaard
  • Karin E. Smedby
  • Sandra Eloranta
  • Peter de Nully Brown
  • Christoffer Johansen
  • Peter Kamper
  • Gustaf Ljungman
  • Lisa Lyngsie Hjalgrim
  • Henrik Hjalgrim

• P063 (0144) Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First interim results of ongoing translational study.

  • Tomas Kozak
  • Jiri Horacek
  • Heidi Mocikova
  • Lubica Gaherova
  • Dan Fayette
  • Lucie Geislerova
  • Ivana Karlova
  • Jana Markova

• P064 (0146) Cause-specific mortality among Hodgkin lymphoma survivors up to 35 years after treatment

  • Simone de Vries
  • Michael Schaapveld
  • Pieternella J. Lugtenburg
  • Laurien A. Daniëls
  • Eefke J. Petersen
  • Josée M. Zijlstra
  • Gustaaf W. van Imhoff
  • Richard W.M. van der Maazen
  • Max Beijert
  • Anna M. van Eggermond
  • Leontien C.M. Kremer
  • Marieke W.J. Louwman
  • Marnix Lybeert
  • Jan Paul de Boer
  • Berthe M.P. Aleman
  • Flora E. van Leeuwen

• P065 (0150) Elevated neutrophil-to-monocyte ratio is associated with decreased overall survival at 5 years in classic Hodgkin lymphoma

  • D. Neves
  • A. Roque
  • C. Afonso
  • A. Pinto
  • D. Mota
  • R. Guilherme
  • M. Gomes
  • L. Ribeiro

• P066 (0154) eBEACOPP FOR FRONT-LINE TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) IN THE REAL WORLD SETTING

  • Sandra Basic-Kinda
  • Dino Dujmovic
  • Ivo Radman
  • Martina Moric Peric
  • Ida Hude
  • Nadira Durakovic
  • Marijo Vodanovic
  • Margareta Dobrenic
  • Marko Kralik
  • Lea Galunic-Bilic
  • Snjezana Dotlic
  • Igor Aurer